Acurox®

  Commercial Agreements
 
  
 
Home
PR 10/27/2008
PR 10/13/2008
PR 10/10/2008
PR 09/02/2008
PR 07/30/2008
PR 07/21/2008
PR 06/30/2008(1)
PR 06/30/2008(2)
PR 06/17/2008
PR 06/03/2008
PR 06/02/2008
PR 05/27/2008
PR 04/30/2008
PR 04/24/2008
PR 03/24/2008
PR 03/05/2008
PR 02/27/2008
PR 01/31/2008
PR 01/24/2008
PR 12/10/2007
PR 12/04/2007
PR 11/02/2007
PR 10/31/2007 (1)
PR 10/31/2007 (2)
 
PR 09/02/2008

 

                  

Text Box: Acura Pharmaceuticals Contact:             Peter A. Clemens, SVP Investor Relations & CFO  847-705-7709

ACURA PHARMACEUTICALS, INC. ANNOUNCES

RETURN OF PRESIDENT AND CEO FROM MEDICAL LEAVE

Palatine, IL September 2, 2008: Acura Pharmaceuticals, Inc. (NasdaqCM: ACUR) announced today that Andy Reddick has resumed full responsibilities as President and Chief Executive Officer following a medical leave of absence initiated in February of this year.  The Company expects Mr. Reddick’s travel schedule will be limited for the foreseeable future. 

About Acura Pharmaceuticals, Inc. 

Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in research, development and manufacture of innovative Aversion® (abuse deterrent) Technology and related product candidates.  For more information, please visit www.acurapharm.com.

 

Any questions or comments regarding Press Releases should be directed to our department of Investor Relations.

Return to the Press Release Archive

 
 
 

 
Home   Sitemap
Copyright © 1998-2008 Acura Pharmaceuticals.  All rights reserved.